Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.81 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8350819 | 0.99 | OPRM1 (0.79) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL476404 | 0.90 | OPRM1 (1.00) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| Hydrochloric Acid SCHEMBL2473959 | 0.88 | OPRM1 (0.97) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL30702525 | 0.88 | OPRM1 (0.74) | OPRM1OPRL1CHRM4OPRD1 | |
| SCHEMBL3895012 | 0.87 | OPRM1 (0.83) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL8350406 | 0.86 | OPRM1 (0.81) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL701266 | 0.85 | OPRM1 (0.75) | OPRM1OPRL1CHRM4OPRD1 | |
| SCHEMBL31567223 | 0.85 | OPRM1 (0.71) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL8350152 | 0.85 | OPRM1 (0.75) | OPRM1OPRL1CHRM4OPRD1DRD2 | |
| SCHEMBL3406514 | 0.83 | OPRM1 (0.81) | OPRM1OPRL1CHRM4OPRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943144-B | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-115943144-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114075175-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-104069112-A | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INT | 2014-10-01 | — | — | CN | disclosed |
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| CN-101827852-B | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INT | 2014-07-30 | — | — | CN | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2380891-B1 | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2013-12-11 | — | — | EP | disclosed |
| EP-2380891-A1 | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2215092-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1558577-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004005256-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | OPRM1 139/4885OPRL1 21/4885CHRM4 73/4885 |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | OPRM1 1693/4885OPRL1 948/4885CHRM4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.